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ABSTRACT
Aims To investigate clustering of all-cause and overdose deaths after a transfer of patients and their care to alternative
treatment provider and after the end of opioid substitution therapy (OST) in opioid-dependent individuals in specialist ad-
diction treatment. Design, Setting and Participants Mortality data were identiﬁed within a sample of 5335 patients
with opioid use disorder who had received OST treatment between 1April 2008 and 31December 2013 from a largemen-
tal health-care provider in the United Kingdom. We investigated the circumstances and distribution of the 332 deaths
identiﬁed within the observation window with a speciﬁc focus on overdose deaths (n = 103) after a planned discharge,
dropout and transfer between services. Measurements Crude mortality rates for overdose mortality 14 days, 28 days
and more than 1 month after the end of treatment/transfer for overdose mortality. Findings Of 47 individuals who died
from overdose after having been transferred between services, nine died during the ﬁrst 2 weeks [crude mortality rate
(CMR) = 136.4, 95% conﬁdence interval (CI) = 64.3–243.1] and a further ﬁve died during the ﬁrst month post-
transfer (CMR= 79.5, 95% CI = 44.2–129.7). Of the 32 individuals who died from overdose after planned OST cessation,
ﬁve died during the ﬁrst 2 weeks (CMR=151.5, 95%CI = 51.1–319.0) and a further four died during the ﬁrst month post-
discharge (CMR = 82.6, 95% CI = 38.4–151.0). Conclusions In the United Kingdom, opioid-dependent people who are
transferred to an alternative treatment provider for continuation of their opioid substitution therapy experience high over-
dose mortality rates, with substantially higher rates during the ﬁrst month (especially during the ﬁrst 14 days) following
transfer.
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INTRODUCTION
Research has shown consistently that opioid substitution
therapy (OST) is associated with reduced mortality (e.g.
[1,2]). More recently, it has also been identiﬁed that there
is a short-lived substantial excess mortality after termina-
tion of OST. In a national primary-care cohort in the
United Kingdom, the risk of death was eightfold greater
in the month immediately after the end of OST [2]. Similar
ﬁndings were found internationally [3–5], but none has
examined interruptions to continuity of care, such as
transfers of patients to alternative services or care
providers. Reduced physiological tolerance that occurs
with interruption of maintenance therapy is a well-known
overdose risk [6]. However, at present very little is known
with regard to destabilization that may occur with changes
to service delivery, such as those due to cuts in resources or
reorganizational changes. These occur frequently, espe-
cially currently in the United Kingdom, and is an area of
concern [7].
We are currently investigating mortality patterns
among patients with opioid use disorder who have received
OST treatment using data from a large secondary mental
health-care provider [8,9]. Within this work, we have
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examined clustering of all-cause and overdose deaths in
opioid-dependent individuals in specialist addiction treat-
ment during the period (a) immediately after a transfer of
patients and their care to alternative treatment provider
and (b) after the end of opioid substitution therapy (OST).
METHODS
Study setting
The South London and Maudsley NHS Foundation Trust
(SLaM) is one of the largest specialist mental health-care
services in Europe providing, within the framework of the
British National Health Service (NHS), comprehensive
mental health-care and addiction services to a catchment
population of approximately 1.36 million residents
throughout seven multi-cultural, ethnically diverse, highly
dense boroughs of London. Within the framework of the
NHS in the United Kingdom, mental health trusts have
close to a 100% monopoly for service provision to their
assigned geographic catchment [8]. In 2008, the Clinical
Record Interactive Search (CRIS) was developed, and
comprises patients’ electronic health records in a de-
identiﬁed format, allowing researchers to search and
retrieve complete case records for analysis. There are
currently more than 260000 patients represented on the
system. CRIS is approved as a data set for secondary
analysis by the Oxfordshire Research Ethics Committee
C (reference 08/H0606/71 + 5), and its protocol is
described in detail elsewhere [8,9].
Study sample
The study sample comprised patients diagnosed with pri-
mary or secondary opioid use disorder (OUD; ICD-10: F11
[9]) between 1 April 2008 and 31 December 2013 who
died within the same observation period.
Every death in the United Kingdom is reported to the
Ofﬁce for National Statistics (ONS) General Records Ofﬁce,
which is then conveyed to the NHS Care Records Service
and available to all NHS organizations, and consequently
in CRIS. This identiﬁes deaths within the observation pe-
riod for both current and previous SLaM patients. The full
procedure for identifying and conﬁrming SLaM patient
deaths has been described elsewhere [10]. In addition, a
linkage to data derived speciﬁcally from death certiﬁcates
allowed us to establish the recorded underlying cause of
each death in those where this information was available.
Diagnoses were derived from their designated SLaM
electronic health records (EHR) structured ﬁelds and from
free-text ﬁelds using natural language processing (NLP).
The NLPapplication for ‘diagnosis’ extracts any text strings
associated with a diagnosis statement in order to supple-
ment the structured ﬁelds, the performance of which has
been reported elsewhere [8].
Measures and calculations
The present study investigated potential clustering of
deaths (a) after a clinically planned termination of OST
and also (b) after a transfer of patient and their care to an-
other service or care provider, with intention for continua-
tion of OST. Themain characteristic of interest in this study
was the timing of death, speciﬁcally overdose deaths, in
OUD patients who were prescribed OST treatment. By
searching backwards from the date of death until the latest
discharge/transfer/dropout, the study measures propor-
tions of all-cause mortality within the 14/28/29+ days
post-discharge/transfer/dropout. For overdose mortality
speciﬁcally, crude mortality rates were calculated and
Kaplan–Meier curves used to visualize the results. Rate
ratio for all post-treatment groups combined (planned
cessation/transfer/dropout) and overdose mortality within
28 days and 29+ days were also calculated.
Treatment episodes
Using CRIS, we extracted de-identiﬁed individual records
on all patients with OUD who died between 1 April 2008
and 31 December 2013. Searching backwards from each
death date, we looked for the start- and end-dates of the
most recent OST treatment episode. This information was
derived primarily from treatment care plan notes, with
each OST treatment episode starting with the date of the
ﬁrst prescription for substitute opioids relating to most
recent treatment episode and ending with the expiry of
their last prescription. The speciﬁc OST medication last
prescribed was also noted.
In all cases, a search through discharge notes and free-
text ﬁelds, including event notes and correspondence, was
also conducted manually for validation purposes and to
supplement data not available in the structured ﬁelds. Par-
ticular attention was given to treatment episodes with a
gap of fewer than 28 days between the end of one episode
and the start date of the next. In such cases, examination of
event and discharge notes was particularly useful, as it
allowed us to establish whether a patient genuinely
stopped and restarted their treatment during a 4-week
period. We adopted the ‘28-day rule’ from Cornish and
colleagues [2], where a gap of fewer than 28 days between
the end of one treatment and the start of the next is not
considered long enough for a patient to genuinely stop
and restart treatment, and is considered as continuity of
the previous treatment episode.
Categorizing reasons for end of treatment
Reasons for cessation of OST treatment were extracted
from patients’ treatment care plans, in discharge notes
and other free-text ﬁelds. By cross-examining these
sources, we categorized reasons for end of treatment into
the following: (1) ‘planned end of treatment’ (patients with
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a clinically planned discharge following cessation of OST);
(2)’ transfer’ (patients whowere transferred to another ser-
vice or care provider who would then take over patients’
care including OST prescribing); (3) ‘dropout’ (patients
with a clinically unplanned OST cessation, such as non-
compliance, failure to attend key-working sessions and/or
failure to collect prescribed OST medications); and (4) ‘died
in treatment’ (if death occurred during an OST treatment
episode). Types of transfer were also noted.
RESULTS
Sample characteristics
The total number of patients with a primary or secondary
ICD10 F11 OUD diagnosis within the observation window
was 5335, with 385 all-cause deaths identiﬁed in this sam-
ple. Of the 385 individuals who died, 53 (14%) were never
prescribed OST within SLaM and/or their records
contained no information with regard to their treatment
history, and were therefore excluded from analysis. A
further 116 (35%) of the remaining 332 patients died
while still in OST treatment in SLaM, and hence were not
considered further in this analysis of deaths post-OST
treatment and post-transfer.
The remaining sample of 216 deaths comprised 66
patients with a planned termination of OST treatment,
109 who were transferred to another service or care
provider and 41 who dropped out of OST treatment.
As presented in Table 1, most patients were male, with
mean age of 45 years at the time of their death. The me-
dian duration of patients’ last OST treatment episode was
just below 8 months (235.5 days, interquartile range
52–560 days) and the median interval between end of
treatment/transfer and deathwas almost 1 year (349 days,
interquartile range 62–800 days). Most destinations for
transfers between services were primary care, followed by
independent/third-sector drug treatment providers, trans-
fer to alternative (usually out-of-area) community and
drug alcohol services, and to general hospitals.
All-cause mortality
Under the assumption that the number of patients under
treatment remained constant throughout the observation
window, we observed what appears to be a higher concen-
tration of all-cause deaths within a month after a planned
end of OST treatment and also high concentrations of
deaths during the ﬁrst month after a transfer between ser-
vices, even when continuation of OST treatment was ar-
ranged. Of the 66 individuals who died after a planned
termination of OST treatment, 27 (41%) died within
180 days of treatment cessation, including 12 of those be-
ing within the ﬁrst 28 days and seven within the ﬁrst fort-
night post-termination. Of the 109 who died after transfer
between services, 43 (39%) died within 180 days of this
transfer, including 26 dying in the ﬁrst 28 days and 17
within the ﬁrst fortnight post-transfer. Similarly, of the 41
who died after having dropped out of treatment, 12
(29%) died within 180 days of this transfer, with four of
these being within the ﬁrst fortnight post-dropout (details
not shown in the Tables).
Overdose mortality
Our primary interest was in deaths caused by fatal over-
dose. We were able to ascertain the cause of death in
96% of patients (208 of 216). Overdose fatalities were the
most common (103; 49%) followed by hepatic-related
deaths (30; 14%) and other natural causes (30; 14%).
Other causes of death in this sample were infectious disease
(12; 6%), pneumonia and other pulmonary causes (15;
7%), other unnatural causes (15; 7%) and unspeciﬁed
(3; 1%). To establish whether transfer of care and termina-
tion of OST treatment were associated with increased risk
of overdose death, we restricted our further analysis to fatal
Table 1 Sample characteristics.
n (%)
Total study sample 216
Males 151
(69.9)
Age (years)
≤ 29 17 (7.9)
30–39 55 (25.5)
40–49 73 (33.8)
50–59 49 (22.7)
60+ 22 (10.1)
Planned OST end 66 (30.6)
Dropouts 41 (19)
Transfer between services 109
(50.5)
Transfer to primary care 42 (38.5)
Transfer to independent/third-party sector 21 (19.3)
Transfer to alternative community drug treatment
service
16 (14.7)
Transfer to general hospital 14 (12.8)
Transfer to prison 5 (4.6)
Other transfers 11 (10.9)
Last prescribed medication
Methadone 179
(82.9)
Buprenorphine 31 (14.3)
Other (diamorphine, Suboxone, morphine) 6 (2.8)
Last treatment episode duration
One month or less 37 (17.1)
Between 1 and 6 months 59 (27.3)
Between 6 months and 1 year 43 (19.9)
More than 1 year 77 (35.6)
OST = opioid substitution therapy.
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overdoses only. Of the 103 individuals who died of over-
dose, 47 were in the post-transfer subgroup and 32 oc-
curred after a planned end of OST, and with high
clustering of overdose deaths occurring in both subgroups.
The remaining 24 individuals who fatally overdosed had
dropped out of treatment.
More speciﬁcally, 20 of 47 (43%) of the post-transfer
overdose deaths occurred within 180 days, nine of whom
died in the ﬁrst 2 weeks from a total of 14 who died in
the ﬁrst month. Similarly, 18 of 32 (56%)overdose deaths
after planned OSTcessation occurred within 180 days, ﬁve
of whom died in the ﬁrst 2 weeks from a total of nine who
died in the ﬁrst month. Of the 24 overdoses which occurred
in the dropout group, ﬁve occurred within 180 days
but none were recorded within the ﬁrst fortnight.
Figure 1 show the distribution of overdose deaths within
180 days post-transfer with continuation of OST treatment
and post-treatment with planned cessation of OST,
respectively.
By looking backwards from date of death until the clos-
est discharge date, we were able to calculate person-days in
this sample (Details shown in Table 2). First, combining the
three reasons for OST treatment end (transfer, planned dis-
charge and dropout), the total follow-up time was 42716
person-days, with 310 person-days in the group who fa-
tally overdosed in the ﬁrst 28 days after post-OST
Table 2 Crude mortality rates per 1000 person-days in OUD patients who died of overdose (n = 103).
n Overdose deaths Person-days (time between treatment cessation/transfer and death) Rate per 1000 person-days (95% CI)
Planned cessation/transfer/dropout
≤ 14 days 14 99 141.4 (80.0–226.0)
≤ 28 days 24 310 77.4 (50.2–113.0)
29 days+ 79 42405 1.9 (1.5–2.3)
Planned OST cessation
≤ 14 days 5 33 151.5 (51.1–319.0)
≤ 28 days 9 109 82.6 (38.4–151.0)
29 days+ 23 10184 2.26 (1.43–3.39)
Transfer
≤ 14 days 9 66 136.4 (64.3–243.1)
≤ 28 days 14 176 79.5 (44.2–129.7)
29 days+ 33 17061 1.9 (1.3–2.7)
Drop-out
≤ 14 days 0 – –
≤ 28 days 1 25 40.0 (1.01–203.5)
29 days+ 23 15160 1.52 (0.96–2.28)
OUD = opioid use disorder; OST = opioid substitution therapy; CI = conﬁdence interval.
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Figure 1 Kaplan–Meier survival curves for time since South London and Maudsley NHS Foundation Trust (SLaM) treatment cessation/transfer (in
days) for overdose deaths, stratiﬁed by reasons for end of treatment or transfer (showing ﬁrst 180 days). OST = opioid substitution therapy [Colour
ﬁgure can be viewed at wileyonlinelibrary.com]
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cessation/transfer, andwith a rate of 77.4 deaths per 1000
person-days compared with a rate of 1.9 deaths per 1000
person-days in the group who died of overdose after the
ﬁrst month of treatment cessation/transfer. The rate ratio
comparing the two groups was 41.5 (95% conﬁdence in-
terval (CI) = 5.1–66.3, P < 0.0001]. Figure 1 displays
the survival probabilities for time since end of
treatment/transfer and overdosemortalitywithin 180 days
after end of treatment, stratiﬁed by reasons for end of treat-
ment, showing a reduced survival predominantly in the
transferred and planned OST cessation groups.
DISCUSSION
This study examined circumstances surrounding the
deaths of patients with a diagnosis of opioid use disorder
who had received OST treatment in a large mental
health-care service, within a nearly 5-year observation pe-
riod. In addition to substantial clustering of deaths in the
early post-OST period, as reported by others [2,3,6], there
was also a substantial excess mortality, and especially over-
dose mortality, in the period immediately following transfer
of patients and their care to a different treatment care pro-
vider, with this excess mortality pronounced in the ﬁrst
month post-transfer.
Increased risk of death immediately after dropout from
treatment may not be surprising [11], and overdose risk
post-termination of OST treatment is already recognized
[3,5]. However, it is counterintuitive that death rates were
higher for patients with planned discontinuations
compared to patients who dropped out. Furthermore, our
ﬁnding of a marked excess of overdose deaths in the period
immediately after transfers of patients and their care
despite planned continuation of OST treatment is new
and unexpected. Large ‘transferred’ subgroups included
patients experiencing transitions from secondary to
primary care (i.e. opioid maintenance under the care of a
general practitioner) or to large independent care-provider
organizations who had secured new NHS contracts after
the introduction of competitive tendering procedures
[12]. If the purpose of such reorganization is to achieve
greater effectiveness and more cost-effective use of re-
sources, then it might have been expected that we would
ﬁnd successful transfer of patients and their treatments, pa-
tient stability and stable or lowered risk of mortality [13];
instead, however, our analysis indicated a high number of
fatal overdoses, particularity during the ﬁrst month post-
transfer. This needs deeper and wider exploration.
Little is known about the destabilization that may ac-
company changes to service delivery. The present data did
not allow us to ascertain what happened to patients after
transfer. Consequently, we were not able to establish
whether any failures had occurred during the period of
transition itself, or whether any destabilization occurred af-
ter a successful transition to the new care provider.
Due to data constraints which prevented from the con-
struction of a cohort, the current analyses were limited to
crude associations and included only the most recent
OST cessation. Nonetheless, these ﬁndings provide impor-
tant insights into practice, the impact of service organiza-
tion (including service reorganizational changes) and the
associated risks of overdose deaths.
This study urgently needs fuller exploration and repli-
cation. Further investigations should establish what hap-
pens to patients after transfer. Before any potential
explanations are discussed with regard to the mechanisms
behind excess deaths post-transfer with continuation of
OST, further investigations should focus on exploring these
ﬁndings using extended data and inferential statistics, as
well as service-user and service-provider consultations. If
these results are conﬁrmed in subsequent studies, clini-
cians, care providers and commissioning bodies need to
be aware of the marked excess of overdose deaths after
transfers of patients and their care, even where continua-
tion of OST is planned. Any transfer of patients whether
due to escalation of treatment (e.g. to an in-patient unit)
or as part of successful recovery (e.g. from an in-patient
unit to rehabilitation care) needs to be undertaken with
caution.
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